1 in 10 antibiotic prescriptions fail, according to new research
One in 10 antibiotic prescriptions ‘fail,’ according to 20-year study by Cardiff University in Wales. The researchers set out to assess the treatment failure rates in UK primary care, focusing on upper respiratory tract infections, lower respiratory tract infections, skin and soft tissue infections and acute otitis media.
The research showed that between 1991 and 2012, overall antibiotic treatment failures rose from 13.9% in 1991 to 15.4% in 2012, indicating an increase of 12%. In this period, however, treatment for lower respiratory tract infections was the least successfully-treated of all infection classes, showing an increased failure rate of 35%.
Failure rates high in trimethoprim
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze